Tina Lujan, LPN in Tijeras, NM - Licensed Practical Nurse

Tina Lujan, LPN is a Licensed Practical Nurse based in Tijeras, New Mexico. Tina Lujan is licensed to practice in New Mexico (license number L20595) and her current practice location is 150 Brannan Rd, Tijeras, New Mexico. She can be reached at her office (for appointments etc.) via phone at (505) 967-9977.

NPI number for Tina Lujan is 1689992422 and her current mailing address is 150 Brannan Rd, Tijeras, New Mexico. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1689992422.

Contact Information

	Tina Lujan, LPN
	150 Brannan Rd, Tijeras, NM 87059-7801
	(505) 967-9977
	Not Available

Provider's Profile

Full Name	Tina Lujan
Gender	Female
Speciality	Licensed Practical Nurse
Location	150 Brannan Rd, Tijeras, New Mexico
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1689992422
Provider Enumeration Date: 05/04/2010
Last Update Date: 05/04/2010

Medical Identifiers

Medical identifiers for Tina Lujan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1689992422	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
164W00000X	Licensed Practical Nurse	L20595 (New Mexico)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Tina Lujan is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Tina Lujan, LPN 150 Brannan Rd, Tijeras, NM 87059-7801 Ph: (505) 967-9977	Tina Lujan, LPN 150 Brannan Rd, Tijeras, NM 87059-7801 Ph: (505) 967-9977

News Archive

Magnetic nanochain detonates chemo barrage inside tumors

Medicine-toting nanochains slip into tumors and explode a chemotherapy drug into hard-to-reach cores of cancer, engineers and scientists at Case Western Reserve University report.

Clinical Genomics introduces new blood-based test for CRC recurrence monitoring

Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced the launch of Colvera, a blood-based test for colorectal cancer (CRC) recurrence monitoring. Colvera is the result of a decade of research, development and clinical validation in more than 4,000 patients.

EpiCept to receive $1.9 million in net proceeds

EpiCept Corporation announced today that it has entered into definitive agreements for the purchase of approximately 3.3 million shares of its common stock at $0.61 per share, and five-year warrants to purchase up to approximately 1.3 million shares of common stock at an exercise price of $0.56 per share, exercisable immediately.

Breast-conservation therapy and mastectomy provide similar survival rates for early-stage breast cancer

Young women with early-stage breast cancer have similar survival rates with a lumpectomy and radiation treatment, known as breast-conservation therapy, as with mastectomy, a new study conducted at the University of Maryland has found. The results of the analysis of nearly 15,000 patients listed in a nationwide cancer registry will be presented at the 2011 Breast Cancer Symposium to be held Sept. 8-11 in San Francisco.

Tina Lujan, LPN - Licensed Practical Nurse in Tijeras, NM